Karl-heinz Klempnauer

Wilhelm Klemm Str. 2
Muenster, NW 48149, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Transcription Factor MYB as Therapeutic Target: Current Developments.

Transcription Factor MYB as Therapeutic Target: Current Developments.

Journal: International journal of molecular sciences

Published: January 28, 2024

C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.

C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.

Journal: Oncotarget

Published: March 13, 2023

A New Naphthopyran Derivative Combines c-Myb Inhibition, Microtubule-Targeting Effects, and Antiangiogenic Properties.

A New Naphthopyran Derivative Combines c-Myb Inhibition, Microtubule-Targeting Effects, and Antiangiogenic Properties.

Journal: ACS medicinal chemistry letters

Published: August 25, 2022

Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities.

Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: July 31, 2022

Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner.

Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner.

Journal: Cells

Published: March 03, 2022

Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.

Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.

Journal: Molecules (Basel, Switzerland)

Published: March 02, 2022

A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells.

A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells.

Journal: Cancer letters

Published: December 28, 2021

C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.

C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.

Journal: Experimental hematology

Published: December 03, 2021

Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity.

Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity.

Journal: Cancers

Published: November 22, 2021

Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824.

Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824.

Journal: BBA advances

Published: October 16, 2021

Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.

Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.

Journal: Cancer letters

Published: April 22, 2021

The CDC37-HSP90 chaperone complex co-translationally degrades the nascent kinase-dead mutant of HIPK2.

The CDC37-HSP90 chaperone complex co-translationally degrades the nascent kinase-dead mutant of HIPK2.

Journal: FEBS letters

Published: January 17, 2021

Showing 1-12 of 38

Last Updated: 09/26/2026